IMMUNOVATIVE ANNOUNCES TODAY SERVERAL IMPROVEMENTS TO IT"S FORMULATION PROCESS

Frozen T-Stim batches are converted to AlloStim in a 4h incubation process.   Previously, the incubation media contained bovine serum.  Company scientists have now developed a method to eliminate the use of animal derived products in the formulation process. Scientists have also developed a customized, closed, sterile disposable product and successfully transferred this technology to the final formulation process.

The closed, sterile environment prevents accidental contamination of the formulated product.  Formulated AlloStim has a 72h shelf life. However, it takes 14 days to confirm the formulation was sterile. Accordingly, there is risk of infusing a contaminated product into a patient.  Company scientist have now developed a method to detect any contamination in the formulated product within 24h.  This rapid microbiological test provides another level of safety to our product. These developments highlight our commitment to patient safety as our highest priority.

SPECIALITY INFORMATION

patients


Treatment strategy designed to use the power of the human immune system to kill tumors and prevent their recurrence.
No requirement for a matched donor or chemotherapy/radiation conditioning prior to treatment.
Innovative technology – proven and non-toxic.
read more

Healthcare professionals


Therapeutic anti-tumor vaccine developed from core break-through technology called the "Mirror Effect™“ which opens a pathway to treating patients with metastatic cancer that have failed all available therapy options.
Elicits a GVT-like mechanism without the GVHD toxicity.
read more

Investors


Privately-held Israeli biopharmaceutical company spin out from Hadassah-Hebrew University Medical Center with headquarters in Jerusalem.

Over 200 individual private shareholders and grant support from the Israel Office of the Chief Scientist.
read more